News

< Back to News

ASCO17 Presentations to Watch: Part I

May. 30, 2017

To put it simply, the annual meeting of the American Society of Clinical Oncology (ASCO) might be the most important moment of the year for cancer research news. With over 35,000 attendees descending on Chicago from all over the world, ASCO is the largest gathering of cancer research in the world. Taking place this year from June 2-6, ASCO is the meeting where researchers and companies hope to announce some of their most meaningful clinical trial results because they know the news will be heard in front of the largest and most respected audience in the industry.

The Cancer Immunotherapy ETF (Nasdaq: CNCR) team watches ASCO closely because cancer immunotherapy research continues to play a growing role. In fact, ASCO named immunotherapy as the Society’s “advance of the year” for a second year in a row for 2017. Given the importance, we wanted to highlight 10 key immunotherapy presentations to watch for at ASCO17. Today we are publishing the first five below in Part I of this post. Please watch for Part II to be published on Friday, June 2nd with an additional five.

text

INCYTE (NASDAQ: INCY)

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

One of the biggest themes in research today is using immunotherapy drugs together in a combination approach to treatment. Immunotherapy is not one thing and there are many different pathways that might elicit an immune response against cancer. The idea behind combos is that you might see a stronger immune response that can help more patients respond to treatment by utilizing different pathways. Incyte is an emerging leader in this combination approach via a drug they are developing called epacadostat. It targets a pathway called IDO.

At ASCO, Incyte and its partner Merck are presenting data from a study where they have combined Incyte’s IDO inhibitor epacadostat and Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in patients with non-small cell lung cancer. Keytruda is already approved in lung cancer so the idea is to see if adding epacadostat on top of it will boost the number of lung cancer patients who benefit from Keytruda alone. Incyte and Merck plan to start a pivotal phase III study of this combination in lung cancer later this year so the ASCO data is important because it might provide a hint at that study’s chances of success.

Earlier this month we have already seen some encouraging preliminary data from the ASCO trial. 35% (14/40) of lung cancer patients had an overall response to the combination of epacadostat and Keytruda, which compares to 18% seen in studies on Keytruda alone. However, new data at the conference will be needed to provide a more complete picture. A longer follow-up time will be presented so researchers can see what percentage of those responses have been durable and how many patients have actually seen their cancer stop progressing altogether. Those will be important clues about the prospects of this IDO/PD-1 combination.

text

BLUEBIRD BIO (NASDAQ: BLUE)

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

CAR-T is the type of immunotherapy where researchers reprogram a patient’s own T-cells and tell them what to look for in the body and destroy it. This approach has worked especially well in certain types of leukemia and lymphoma because those cancers express a protein marker called CD19 that can be used as an obvious target for the T-cells. A next advance that many people are looking for out of CAR-T is whether there are more targets and types of cancers this process might work for. One possibility is called BCMA, which is expressed on multiple myeloma. By programing T-cells to look for and destroy BCMA, CAR-T might be used to treat this additional type of cancer. Bluebird is a leader in this and started a first in human study of their BCMA CAR-T last year.

Last November bluebird presented data from the first 11 patients in a study who received the company’s BCMA CAR-T. Of the six patients who received the two highest doses, 100% saw an objective response to the treatment and two received a stringent complete response, which means there was an absence of all cancer after the treatment. That of course is the best outcome possible so it sparked optimism about the potential for BCMA CAR-T. While the November data was encouraging, it is essentially as preliminary as trial data gets so researchers will be interested to see results from more patients and over a longer period of time. This is also important from a safety standpoint. The side effect profile seen in some CAR-T studies has been difficult to manage, although bluebird saw nothing concerning like that in their initial patients.

At ASCO, bluebird will provide an update from this same study now that more time has passed. The new data will include safety and efficacy data from 18 patients with up to 12 months of follow-up. The hope is that the responses seen previously (especially the complete responses) will stay durable over this longer period of time, and that new patients will respond well to the treatment as well. It would be especially great to see more complete responses. In terms of safety, a hope is that bluebird continues to see little or no toxicities like cytokine release syndrome or neurotoxicity, two of the main side effects that have impacted other CAR-T therapies.

text

KITE PHARMA (NASDAQ: KITE)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Kite is a leader in the CAR-T approach to immunotherapy and, along with Novartis, is battling to become one of the first companies to have a CAR-T therapy approved for commercialization by FDA. In Kite’s case, the approval they are seeking is to use CAR-T against an aggressive form of non-Hodgkin lymphoma (NHL). They filed their application with FDA in late March after announcing positive data from a pivotal study in NHL using the company’s KTE-C19 CAR-T. Kite’s competitor Novartis is likewise seeking approval for CAR-T after announcing positive results in a different type of cancer, pediatric acute lymphoblastic leukemia (ALL). These are the early days of CAR-T so hopefully NHL and pediatric ALL will be the first of many cancers CAR-T works in and is ultimately approved for by FDA.

At ASCO, we will learn more about Kite’s chances of expanding their CAR-T success beyond NHL. They will present updated data from a study of CTE-C19 CAR-T in adults with acute lymphoblastic leukemia (ALL). As noted above, their competitor Novartis has already demonstrated positive trial results in pediatric ALL and is seeking FDA approval in that indication. Therefore, one thing we will learn more about from Kite’s ASCO data is the difference between how adults and children respond to CAR-T. Juno Therapeutics, another company in the CAR-T space, had to halt a trial in adult ALL last year due to severe toxicities so researchers at ASCO will be paying particular attention to Kite’s side effect profile in this study. One key question is whether those problems were unique to Juno or if adult ALL is particularly difficult to treat with CAR-T for all companies.

text

BRISTOL-MYERS SQUIBB (NYSE: BMY)

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

As we mentioned in our discussion of Incyte above, immunotherapy is not one thing and researchers are looking at many different pathways that might elicit an immune response against cancer. The most famous pathway is called PD-1, which is the target behind blockbuster immunotherapy drugs that are already approved by FDA like Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo. There are dozens of other targets currently being researched and time will tell which of them work either alone or in combination with other drugs. Bristol has many such immunotherapy assets in their research pipeline to supplement the success of Opdivo. In fact, as a sign of its leadership in oncology, the company has 80 presentations scheduled for ASCO that compromise over 20 different types of cancer.

One presentation to watch for at the meeting is from a study using Bristol’s anti-LAG-3 asset, BMS-986016. The study is important because this is the first time we have seen efficacy data from Bristol using LAG-3 so researchers will be watching closely to assess its potential as a pathway in immunotherapy. LAG-3 affects T-cell function and therefore is a potential immune checkpoint target like PD-1. This particular ASCO study will be in combination with Opdivo for melanoma. You might already know that Bristol has another immunotherapy drug called Yervoy that is approved in combination with Opdivo for melanoma, but that combination can be hard to tolerate for some patients. This makes the LAG-3 data even more interesting because it will provide clues about whether BMS-986016 is potentially a better partner drug when it comes to the combo approach.

In addition to this LAG-3 study, watch for data from another target, GITR, and combination data Bristol will have with Incyte’s IDO inhibitor epacadostat to be other focuses at ASCO.

text

ZIOPHARM ONCOLOGY (NASDAQ: ZIOP)

Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.

Recurrent glioblastoma is a particularly devastating cancer with a median overall survival of only 6-7 months. New treatments are urgently needed for patients. ZIOPHARM has been developing a gene therapy candidate (Ad-RTS-hIL-12) for recurrent glioblastoma that expresses interleukin-12 (IL-12) when activated by an oral drug called veledimex. This is an immunotherapy approach because IL-12 is a cytokine, a cell-signaling protein that stimulates an immune response to the cancer. Unfortunately IL-12 is too toxic to be used on its own as a traditional therapy for glioblastoma so ZIOPHARM’s idea is that by expressing it locally in a way that can be started or stopped with the oral veledimex, they might be able get the immune system to combat the patient’s tumor in a way that is more tolerable.

At ASCO, ZIOPHARM will present updated data from a dose-escalation study and 20-mg expansion cohort using this gene therapy approach. Given that Ad-RTS-hIL-12 is such a highly technical therapy and that the oral veledimex is designed to start and stop the IL-12 treatment when needed, the safety profile is something that will be particularly noted at ASCO. Researchers will also look for survival trends and other responses to the treatment, and to compare those to what has historically been seen in these poor prognosis patients. ZIOPHARM plans to initiate a pivotal registration study of Ad-RTS-hIL-12 sometime in 2017 and the updated ASCO data will provide a glimpse as to the feasibility of conducting that trial and the likelihood of it succeeding. This is ZIOPHARM’s most advanced program so the results are key for the company.

As you can see, 2017 is setting up to be another very busy year at ASCO for immunotherapy. Don’t forget to look for Part II of our ASCO preview as the conference kicks off on Friday.


  • Loncar Funds
  • P.O Box 15072
  • Lenexa, KS 66285
  • +1 800-617-0004
  • Contact Us

CNCR Prospectus CHNA Prospectus

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 25 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 28 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained at www.loncarfunds.com. Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV. CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.